Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — 43rd Annual J.P. Morgan Healthcare Conference 2025
21 slides from Bico Group Ab Class B's conference presentation, Jan 15, 2025
Slide 1: 43rd Annual J.P. Morgan Healthcare Conference
43 RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE – JANUARY 15, 2025 MARIA FORSS, PRESIDENT & CEO 2025-01-15
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The fol- for publication, release or distribution in the United affect the extent to which a particular projection is real- lowing applies to this document and the information pro- States, the United Kingdom, Australia, Canada or Japan, ised.
Slide 3: Vision and Mission
Vision BICO enables and automates the life science lab of the future Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech 3
Slide 4: BICO in Figures
BICO in Figures Founded in 2016 65+ SEK 2.2bn Global Presence Net Sales No of Markets FY 2023 North Europe America 37% (26) Asia 53% (56) 6% (18) 710+ 46,000+ Rest of Employees the world Installed Instruments 4% (0) 11 Share of sales per geography 12,000+ Q3 2024 vs Q3 2023* Publications Companies 4
Slide 5: Sales, Adjusted EBITDA and Cash Flow from Operating Activities
FY 2022, FY 2023 and R12M Q3 24: Sales, Adjusted EBITDA and Cash Flow from Operating Activities Total Sales Adjusted EBITDA Operational cash flow SEK m SEK m % SEK m 2500 250 20 250 2,250 2,121 2,176 218 18 200 178 2000 200 16 139 150 162 14 100 1500 150 12 50 126 FY 2022 9.7 10 0 FY 2023 R12M 1000
Slide 6: Be the First-choice Lab Automation Partner and Provider of Selected Workflows
Be the First-choice Lab Automation Partner and Provider of Selected Workflows to Pharma and Biotech LIFE SCIENCE LAB AUTOMATION BIOPRINTING SOLUTIONS 6
Slide 7: BICO Offers Solutions in Molecular Biology, Drug Discovery and Synthetic Biology
BICO Offers Solutions Predominantly in Molecular Biology, Drug Discovery and Synthetic Biology BICO focuses on the first three life science value chain steps Life sciences Value chain Drug & Basic research & (Bio)- 1 2 diagnostic 3 4 Clinical use discovery production development Biotechnology BICO’s
Slide 8: BICO Workflow Landscape
Academia BICO Workflow Landscape 8
Slide 9: Strong Customer Base and Relationships in Top Pharma
Strong Customer Base and Relationships in Top Pharma* Biotech Cellino DeepCure Scribe Therapeutics Cosmetics Metagenomi Diagnostics Estée Lauder Pharma & Arpeggio Invitae Charles River Biopharma Laboratories Novo Nordisk AstraZeneca Eli Lilly EMD Sereno Astellas Merck KGaA Pfizer BMS Roche J&J Food
Slide 10: BICO Address Needs Holistically Through End-to-End Workflows
BICO Address Needs Holistically Through End-to-End Workflows Field Molecular biology Drug Discovery SynBio Share of revenue Hit Biologics, Basic Diagnostic Target Lead Animal Clinical proteins, Activity generation & small Today Ambition research testing discovery optimization models trials lead iden
Slide 11: Key Trends for BICO
Key Trends for BICO – Growing demand – Growing adoption of in- for integrated and - Technologies for rapid vitro testing instead of automated workflows compound screening animal testing* in labs for higher and hit to lead generation – Regulatory compliant efficiency and - Increased focus on platform
Slide 12: Total and Serviceable Addressable Market
Total and Serviceable Addressable Market Global TAM (by market segment, 2023, USDbn) Global SAM (by 2023, USDbn) Potential market size, independently from BICO’s ability Market size based on customers BICO can serve with to reach and serve it existing business Total ~3bn, average CAGR: +12% In-vitro
Slide 13: Lab Automation Industry Evolving significantly
Lab Automation Industry Evolving significantly • Market size valued around USD 5.5-6.8bn in 2023 • Growth rate indicated at CAGR 6.3-9.3% in 2023 to 2035 • Integrated automated solutions market we estimate to USD 1.1-1.3 bn and expected to continue to grow faster than the overall lab automation mark
Slide 14: Lab Automation and Selected Workflows are the Cornerstones in BICO's Offering
Lab Automation and Selected Workflows are the Cornerstones in BICO’s Offering Instruments Consumables Bioprinting Lab Automation and selected workflows Services Data, AI and software 14
Slide 15: Updated Strategy BICO 2.0 – Strong Commercial Focus
Updated Strategy BICO 2.0 – Strong Commercial Focus Drive Commercial Excellence Further develop Ensure Enable Provide Scientific Increase integrated Regulatory End-to-End Workflow recurring data, AI and SW Compliance Lab automation Solutions revenue solutions Readiness 15
Slide 16: The Problem / The BICO Solution
The Problem Discovering new drugs and marketable scientific innovations • Takes years of time The BICO Solution • Cost millions to billions of dollars • May be heavily regulated Accelerating scientific research through automation 16 16
Slide 17: Laboratory Automation: The breadth of Solutions
Laboratory Automation: INTEGRATED The breadth of Solutions FULLY- AUTOMATED AUTOMATED SEMI- AUTOMATED MANUAL Connecting equipment through Biosero's Green Button Go® Software 17 17
Slide 18: The Impact of Automation
The Impact of Automation Reduce downstream Increase existing Maximize productivity process and assay equipment capacity to develop of development scientists development by up biopharmaceutical and labs by a minimum to 75% manufacturing processes by of 200% 400% 18
Slide 19: BICO Leads the Way in Solving Challenges in Life Science
BICO Leads the Way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency Speed • Reducing the time to find optimal candidates for treatment therapies Accuracy • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant models
Slide 20: BICO Vision and Strategic Agenda
BICO Vision and Strategic Agenda BICO ENABLES AND AUTOMATES Vision THE LIFE SCIENCE LAB OF THE FUTURE Mission Be the first-choice lab automation partner and provider of selected workflows to pharma and biotech Enable end-to-end Further develop Ensure regulatory Provide scientific Increase Strategic
Slide 21: Slide 21
BICO Group — 43rd Annual J.P. Morgan Healthcare Conference 2025 on 6ix